Smart tech is bettering lives, and a new business partnership is creating a positive change in Asia.
In a move to bring better communication between diabetics and healthcare providers in Japan, Health2Sync has partnered with Novo Nordisk Pharma to improve the outcomes of people living with diabetes. Ed Deng, Co-Founder and CEO of the Health2Sync app and healthcare provider platform and a McIntire Global Advisory Board member, says the Japanese market is ready for the improved treatment innovation his company provides.
Successfully offering the Health2Sync app to users for nearly five years, the Taipei, Taiwan-based company now serves 310,000 registered users. By incorporating a behavioral AI engine that helps patients stick with their diabetes treatment through reminders about meals, exercise, and blood glucose management, Health2Sync (known as SyncHealth app in Japan) is already the top-rated and top-downloaded diabetes-related app in Japan, Taiwan, Hong Kong, and Malaysia.
Combined with pharmaceutical company Novo Nordisk’s recent advancements in smartphone-connected insulin pens, and future aims to wirelessly connect insulin-delivery devices and enable auto-data recording of self-injected insulin, the partnership with Health2Sync has the potential to revolutionize the patient experience.